296 related articles for article (PubMed ID: 10722593)
1. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.
Dreisbach VC; Cowley S; Elkins KL
Infect Immun; 2000 Apr; 68(4):1988-96. PubMed ID: 10722593
[TBL] [Abstract][Full Text] [Related]
2. Francisella novicida LPS has greater immunobiological activity in mice than F. tularensis LPS, and contributes to F. novicida murine pathogenesis.
Kieffer TL; Cowley S; Nano FE; Elkins KL
Microbes Infect; 2003 Apr; 5(5):397-403. PubMed ID: 12737995
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain.
Skyberg JA; Rollins MF; Samuel JW; Sutherland MD; Belisle JT; Pascual DW
Infect Immun; 2013 Sep; 81(9):3099-105. PubMed ID: 23774604
[TBL] [Abstract][Full Text] [Related]
4. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
KuoLee R; Harris G; Conlan JW; Chen W
Vaccine; 2007 May; 25(19):3781-91. PubMed ID: 17346863
[TBL] [Abstract][Full Text] [Related]
5. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge.
Cole LE; Yang Y; Elkins KL; Fernandez ET; Qureshi N; Shlomchik MJ; Herzenberg LA; Herzenberg LA; Vogel SN
Proc Natl Acad Sci U S A; 2009 Mar; 106(11):4343-8. PubMed ID: 19251656
[TBL] [Abstract][Full Text] [Related]
6. Survival of secondary lethal systemic Francisella LVS challenge depends largely on interferon gamma.
Elkins KL; Colombini SM; Meierovics AI; Chu MC; Chou AY; Cowley SC
Microbes Infect; 2010 Jan; 12(1):28-36. PubMed ID: 19781659
[TBL] [Abstract][Full Text] [Related]
7. A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.
Jia Q; Bowen R; Sahakian J; Dillon BJ; Horwitz MA
Infect Immun; 2013 May; 81(5):1550-61. PubMed ID: 23439306
[TBL] [Abstract][Full Text] [Related]
8. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells.
Rhinehart-Jones TR; Fortier AH; Elkins KL
Infect Immun; 1994 Aug; 62(8):3129-37. PubMed ID: 8039881
[TBL] [Abstract][Full Text] [Related]
9. NK cells activated in vivo by bacterial DNA control the intracellular growth of Francisella tularensis LVS.
Elkins KL; Colombini SM; Krieg AM; De Pascalis R
Microbes Infect; 2009 Jan; 11(1):49-56. PubMed ID: 18992838
[TBL] [Abstract][Full Text] [Related]
10. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.
Baron SD; Singh R; Metzger DW
Infect Immun; 2007 May; 75(5):2152-62. PubMed ID: 17296747
[TBL] [Abstract][Full Text] [Related]
11. A novel role for B cells in early protective immunity to an intracellular pathogen, Francisella tularensis strain LVS.
Culkin SJ; Rhinehart-Jones T; Elkins KL
J Immunol; 1997 Apr; 158(7):3277-84. PubMed ID: 9120284
[TBL] [Abstract][Full Text] [Related]
12. Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.
Chiavolini D; Weir S; Murphy JR; Wetzler LM
Clin Vaccine Immunol; 2008 Sep; 15(9):1322-9. PubMed ID: 18614668
[TBL] [Abstract][Full Text] [Related]
13. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
Richard K; Mann BJ; Qin A; Barry EM; Ernst RK; Vogel SN
Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077440
[No Abstract] [Full Text] [Related]
14. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain.
Duckett NS; Olmos S; Durrant DM; Metzger DW
Infect Immun; 2005 Apr; 73(4):2306-11. PubMed ID: 15784575
[TBL] [Abstract][Full Text] [Related]
15. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.
Wayne Conlan J; Shen H; Kuolee R; Zhao X; Chen W
Vaccine; 2005 Mar; 23(19):2477-85. PubMed ID: 15752834
[TBL] [Abstract][Full Text] [Related]
16. Increased susceptibility of IgA-deficient mice to pulmonary Francisella tularensis live vaccine strain infection.
Furuya Y; Kirimanjeswara GS; Roberts S; Metzger DW
Infect Immun; 2013 Sep; 81(9):3434-41. PubMed ID: 23836815
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis.
Chen W; KuoLee R; Shen H; Conlan JW
Microb Pathog; 2004 Jun; 36(6):311-8. PubMed ID: 15120157
[TBL] [Abstract][Full Text] [Related]
18. Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.
Jia Q; Bowen R; Lee BY; Dillon BJ; Masleša-Galić S; Horwitz MA
Vaccine; 2016 Sep; 34(41):4969-4978. PubMed ID: 27577555
[TBL] [Abstract][Full Text] [Related]
19. Specific antibodies protect gamma-irradiated mice against Francisella tularensis infection.
Kubelkova K; Krocova Z; Balonova L; Pejchal J; Stulik J; Macela A
Microb Pathog; 2012; 53(5-6):259-68. PubMed ID: 22841607
[TBL] [Abstract][Full Text] [Related]
20. Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity.
Cole LE; Elkins KL; Michalek SM; Qureshi N; Eaton LJ; Rallabhandi P; Cuesta N; Vogel SN
J Immunol; 2006 Jun; 176(11):6888-99. PubMed ID: 16709849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
